Evidence map›Paper›PMID 34150630›Full record

ArticleFrontiers in oncology2021

Prognostic Implication of a Novel Metabolism-Related Gene Signature in Hepatocellular Carcinoma.

Chaoyan Yuan, Mengqin Yuan, Mingqian Chen, Jinhua Ouyang, Wei Tan, Fangfang Dai, Dongyong Yang, Shiyi Liu, Yajing Zheng, Chenliang Zhou and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. FOXO3 upregulates and activates GSDME to trigger myeloma cell pyroptosis.International journal of biological sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. CENPA-driven STMN1 Transcription Inhibits Ferroptosis in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Chaoyan YuanDepartment of Gynecology, Minda Hospital of Hubei Minzu University, Enshi, China.
Mengqin YuanDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Mingqian ChenDepartment of Gynecology, Minda Hospital of Hubei Minzu University, Enshi, China.
Jinhua OuyangDepartment of Gynecology, Minda Hospital of Hubei Minzu University, Enshi, China.
Wei TanDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Fangfang DaiDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Dongyong YangDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Shiyi LiuDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Yajing ZhengDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Chenliang ZhouDepartment of Intensive Care Unit, Renmin Hospital of Wuhan University, Wuhan, China.
Yanxiang ChengDepartment of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, China.
Wuhan University · CNMinda Hospital · CNRenmin Hospital of Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the main causes of cancer-associated deaths globally, accounts for 90% of primary liver cancers. However, further studies are needed to confirm the metabolism-related gene signature related to the prognosis of patients with HCC.

methodsUsing the "limma" R package and univariate Cox analysis, combined with LASSO regression analysis, a metabolism-related gene signature was established. The relationship between the gene signature and overall survival (OS) of HCC patients was analyzed. RT-qPCR was used to evaluate the expression of metabolism-related genes in clinical samples. GSEA and ssGSEA algorithms were used to evaluate differences in metabolism and immune status, respectively. Simultaneously, data downloaded from ICGC were used as an external verification set.

resultsFrom a total of 1,382 metabolism-related genes, a novel six-gene signature (G6PD, AKR1B15, HMMR, CSPG5, ELOVL3, FABP6) was constructed based on data from TCGA. Patients were divided into two risk groups based on risk scores calculated for these six genes. Survival analysis showed a significant correlation between high-risk patients and poor prognosis. ROC analysis demonstrated that the gene signature had good predictive capability, and the mRNA expression levels of the six genes were upregulated in HCC tissues than those in adjacent normal liver tissues. Independent prognosis analysis confirmed that the risk score and tumor grade were independent risk factors for HCC. Furthermore, a nomogram of the risk score combined with tumor stage was constructed. The calibration graph results demonstrated that the OS probability predicted by the nomogram had almost no deviation from the actual OS probability, especially for 3-year OS. Both the C-index and DCA curve indicated that the nomogram provides higher reliability than the tumor stage and risk scores. Moreover, the metabolic and immune infiltration statuses of the two risk groups were significantly different. In the high-risk group, the expression levels of immune checkpoints, TGF-β, and C-ECM genes, whose functions are related to immune escape and immunotherapy failure, were also upregulated.

conclusionsIn summary, we developed a novel metabolism-related gene signature to provide more powerful prognostic evaluation information with potential ability to predict the immunotherapy efficiency and guide early treatment for HCC.

Indexed as

hepatocellular carcinomaimmunotherapymetabolism-related genesoverall survivalprognostic signature

Identifiers

PMID34150630
PMCPMC8213025
OpenAlexW3170688451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.